Remove 2020 Remove Competition Remove Prescription Remove Sales
article thumbnail

Pharma’s reputational high will be short-lived

World of DTC Marketing

Pharma has gone to court again and again to delay generic competition of biologic drugs. One company AbbVie has used the courts to stop competition of its top drug Humira. By the look of 2020’s results, he’s on the right track—and his compensation shows it. For writing that 2020 success story, CEO Albert Bourla, Ph.D.,

Pharma 186
article thumbnail

Exploring Pharmaceutical Sales Reps Salaries: A Deep Dive

Rep-Lite

As a pharmaceutical sales rep, you undergo a rigorous training program, develop strong relationships with healthcare professionals, and work tirelessly to meet sales targets. You also deal with the challenges of an ever-changing industry landscape, including stiff competition from generic drugs and strict regulation policies.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

Pharma is “big business” that uses excuses to keep prices high

World of DTC Marketing

Seventy-nine percent of Americans think the price of prescription drugs is “unreasonable,” according to a 2019 Kaiser Family Foundation poll , and about 9 in 10 say they support the idea of the government negotiating prices. sales of the 20 top-selling drugs worldwide totaled $101.1 According to Public Citizen : U.S.

Pharma 241
article thumbnail

US legislative update: takeaways for European pharma

European Pharmaceutical Review

In the current US Congressional session, Congress has focused heavily on legislation directed at reducing prescription drug prices. The new law will also require drug manufacturers to pay rebates to Medicare if they increase drug prices faster than consumer inflation.

article thumbnail

Nine for 2023, part three: thriving or surviving?

pharmaphorum

In this final instalment of IQVIA EMEA Thought Leadership’s Nine for 2023 three-part series, focusing on issues that will change the direction of healthcare and the pharmaceutical industry this year, three key competitive issues for pharmaceutical companies in 2023 are assessed.

article thumbnail

PM360 Q&A with Adrian Adams, Chairman & CEO, Impel Pharmaceuticals

PM360

Most recently, he took over the then-called Impel NeuroPharma in May 2020—at the height of the pandemic—and since then has led the company through its first product approval, undergone an initial public offering (IPO), rebranded to Impel Pharmaceuticals, and attracted big interest from Big Pharma in its novel drug delivery technology.

article thumbnail

Two Key Questions About Payer Strategies in 2023

PM360

However, we expect drugs without strong therapeutic alternatives to have an advantage in negotiations, while drugs in highly competitive classes will be negotiating from a weaker position. Given the volume of 340B sales (13% of total U.S. The 340B battle will rage on. The first agent out, Amgen’s Amjevita , launched on Jan.